#Sanyou Biopharmaceuticals #Biologics R&D #Lang Guojun

Sanyou Biopharmaceuticals: Pioneering Accessible Biologics R&D Worldwide

On February 8th, during the 2026 China New Drug Source Innovation Forum held in Shanghai, Lang Guojun, the founder and CEO of Sanyou Biopharmaceuticals, unveiled the compelling story behind the company’s decade-long journey in the biotechnology sector. Established at a time when China's biopharmaceutical innovation ecosystem was still in its infancy, Sanyou has emerged as a global leader in making biologics research and development (R&D) more accessible for clients around the world.

Ten years ago, the scene of biopharmaceuticals in China appeared quite different. The industry was dominated by international pharmaceutical giants, and domestic efforts were often hampered by technological limitations, inadequate financing, and substantial entry barriers. In the midst of these challenges, Lang Guojun and a small team initiated a groundbreaking venture from a modest 107-square-meter laboratory, motivated by a powerful vision of democratizing access to quality antibodies for researchers and drug developers.

Fast forward to the present, Sanyou Biopharmaceuticals has successfully catered to nearly 2,000 clients worldwide, developing an impressive intelligent molecule library worth ten trillion and advancing over ten collaborative projects into the clinical development stage. Lang emphasizes that while drug development is notoriously challenging, making the journey smoother is essential, underlining the company’s mission—to ease the process of producing innovative treatments.

A Decade of Dedicated Effort and Growth

The evolution of the global biologics industry has been remarkable, driven by an increasing demand for innovative treatments for unmet clinical needs. With approximately 2 billion patients worldwide still struggling with various ailments, the potential market for biologics is vast. Industry forecasts predict that global biologics sales could reach around $1.4 trillion, constituting 57% of the overall pharmaceutical market.

Sanyou’s growth echoes this momentum, showcasing a significant shift from 'catching up' to 'defining' biopharmaceutical trends globally. In recent years, the total licensing value from Chinese pharmaceutical firms reached over $130 billion, and the proportion of antibody drugs in these transactions soared, affirming the rapid advancement of China's biopharmaceutical sector.

Yet, Lang notes that innovation in drug R&D resembles a marathon rather than a sprint; it demands a comprehensive, systematic approach that encompasses everything from the initial target selection to the final clinical trials. To facilitate this, Sanyou adopted an open platform model, collaborating with partners and stakeholders to expedite the drug discovery process. This strategy not only focuses on individual successes but also aims to build an ongoing source of innovation that can consistently deliver breakthroughs in the field.

Building a Robust Ecosystem

The company’s commitment to systematic development is evident through its expansive R&D and GMP facilities, now exceeding 20,000 square meters with over 200 talented employees. This growth trajectory has been complemented by a host of certifications, including recognition as a National High-Tech Enterprise. Sanyou's reach spans North America, Europe, and beyond, illustrating the global significance of its mission.

As of now, the organization has executed over 60 collaborations and has significant milestones, with 10 projects having previously completed IND submissions and several progressing to the clinical evaluation stages. Lang believes that Sanyou's strategic approach is pivotal in navigating the complexities of drug development and brings a competitive edge.

Integrating Technology into Development

Central to Sanyou Biopharmaceuticals' forward-thinking strategy is the integration of AI technologies with a super-trillion molecule library. The company foresees AI playing a crucial role in the future of pharmaceutical R&D, and thus, it has put substantial efforts into creating an intelligent Dry-Wet Integration R&D platform. This advanced system aims to rejuvenate the R&D process by effectively integrating computational modeling, AI-driven techniques, and experimental methodologies.

Sanyou Biopharmaceuticals underscores the importance of merging survival strategies with robust capability building. By addressing both research innovation and operational excellence, the company effectively connects real clinical needs with technological solutions across the drug development spectrum.

Currently, Sanyou has more than 100 early-stage projects underway, addressing significant disease areas such as oncology and metabolic disorders. This expansive portfolio showcases the company's ability to validate its platform through real-world projects, reinforcing its systematic approach.

The Collaborative Future of Drug Development

In navigating the challenges within the pharmaceutical landscape, Lang sees a transitional opportunity—a shift from traditional methods towards a collaborative model that mirrors a relay race; where various components of drug development can efficiently pass the baton among different stakeholders to streamline the process.

The